2025
Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments
Pouyan N, Aday J, Harte S, Kaplan C, Williams D, Glynos N, Herberholz M, Kruger D, Barron J, Mashour G, Clauw D, Preller K, Schrepf A, Boehnke K. Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments. Journal Of Psychopharmacology 2025, 39: 489-498. PMID: 40323119, DOI: 10.1177/02698811251330763.Peer-Reviewed Original ResearchConceptsNaturalistic psychedelic usePsychedelic useSymptom changeSymptom improvementAssociated with symptom improvementEffects of psychedelicsPosttraumatic stress disorderIndividual perceptions of selfPerceptions of selfPRISM scoreRepresentations of illnessPsychedelic treatmentStress disorderGlobal ImpressionPsychedelic experiencePictorial representationPictorial Representation of IllnessRetrospective reportsSelf-PerceptionReduced identificationChange scoresRetrospectively assessed changesPGIC scoresPatient Global ImpressionConvenience sampleA Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research
Yaden D, Graziosi M, Owen A, Agin-Liebes G, Aaronson S, Allen K, Barrett F, Bogenschutz M, Carhart-Harris R, Ching T, Cosimano M, Danforth A, Davis A, Garcia-Romeu A, Griffiths R, Grob C, Gründer G, Gukasyan N, Heinzerling K, Hendricks P, Holze F, Horton D, Johnson M, Kelmendi B, Peck S, Koslowski M, Liechti M, Mertens L, Moreno F, Nayak S, Nicholas C, Preller K, Rieser N, Ross S, Sergi K, Sloshower J, Smigielski L, Stenbæk D, Vollenweider F, Weiss B, Wolff M, Yaden M. A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research. Psychedelic Medicine 2025, 3: 1-18. PMID: 40351554, PMCID: PMC12060849, DOI: 10.1089/psymed.2024.0019.Peer-Reviewed Original ResearchResearch settingsSerotonin 2A receptor agonistAcute subjective effectsReflexive thematic analysisPsychological safetyPsychedelic treatmentIdentified themesSerotonergic psychedelicsSubjective effectsPsychological supportThematic analysisMedical staffPsychedelic experienceStates of consciousnessFamily historyPsilocybinReceptor agonistsWell-beingPsilocybin studiesDecades of researchPsychedelicsPsychoeducationPotential contraindicationsLevel of riskAnticipated outcomesThe Contribution of Psychotherapy in Potential Therapeutic Effects of Psychedelics for Treatment of Opioid Use Disorder
Bassir Nia A, Farahmand Y, Griffith G, Ardavan M, Angarita G, Anand A, Pittenger C. The Contribution of Psychotherapy in Potential Therapeutic Effects of Psychedelics for Treatment of Opioid Use Disorder. Current Addiction Reports 2025, 12: 20. DOI: 10.1007/s40429-025-00638-7.Peer-Reviewed Original ResearchEffects of psychedelicsOpioid use disorderConcurrent psychotherapyUse disorderTherapeutic effects of psychedelicsContribution of psychotherapyImpact of psychedelicsSubstance use disordersOpioid withdrawal symptomsTreatment of opioid use disorderFDA-approved medicationsOpioid use disorder treatmentPsychotherapy modalitiesPsychedelic treatmentPsychotherapy componentWithdrawal symptomsPsychotherapyPsychedelic trialsTherapy modelPsychedelicsAcute effectsDisordersAssociated with higher ratesTreatment discontinuationPotential therapeutic effects
2024
Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder
Mohammad Aghaei A, Weleff J, Martins B, Ing K, Fontenele R, Barnett B, Anand A, Bassir Nia A. Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder. Current Addiction Reports 2024, 11: 685-712. DOI: 10.1007/s40429-024-00574-y.Peer-Reviewed Original ResearchTreatment of AUDUse disorderTreatment of alcohol use disordersModalities of psychotherapyAlcohol use disorderPsychedelic treatmentPsychotherapeutic interventionsTreat AUDPsychedelic compoundsPsychedelic trialsPsychotherapySmall numbers of participantsPsychedelicsMagnitude of improvementMethodological shortcomingsAUDNumbers of participantsClinical trialsDisordersReviewed trialsShort follow-up periodFollow-up periodTherapy methodsEmpirical evidenceNo significant differenceMechanisms of therapeutic change after psychedelic treatment in OCD
Maloney G, Ching T, Kichuk S, Pittenger C, Kelmendi B. Mechanisms of therapeutic change after psychedelic treatment in OCD. Psychiatry Research 2024, 336: 115907. PMID: 38615521, PMCID: PMC11190873, DOI: 10.1016/j.psychres.2024.115907.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderMechanisms of therapeutic changeAversive eventsImagery rescriptingPsychedelic treatmentPsychotherapeutic treatmentPsychotherapeutic frameworkSymptom reductionTherapeutic changePsychotherapyNegative emotionsPsychological mechanismsCore beliefsPilot dataNovel treatmentRescriptingEmotionsDisordersSymptomsReprocessingTreatmentBeliefsResistance to first-lineIndividualsIntervention
2023
Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry
Barber G, Dike C. Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry. Psychiatric Services 2023, 74: 838-846. PMID: 36987705, DOI: 10.1176/appi.ps.20220525.Peer-Reviewed Original ResearchConceptsPsychedelic-Assisted PsychotherapyPotential ethical pitfallsEthical pitfallsRigorous scientific inquiryUse of psychedelicsPsychedelic psychotherapyScientific inquiryInformed consentBroader publicPatient vulnerabilityPsychiatric communityAltered statesCurrent enthusiasmPsychiatristsPsychiatryPsychedelic treatmentRole of Psychedelics in Treatment-Resistant Depression
Kamal S, Jha M, Radhakrishnan R. Role of Psychedelics in Treatment-Resistant Depression. Psychiatric Clinics Of North America 2023, 46: 291-305. PMID: 37149346, DOI: 10.1016/j.psc.2023.02.004.Peer-Reviewed Original ResearchProspective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans
Armstrong S, Xin Y, Sepeda N, Polanco M, Averill L, Davis A. Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans. Military Psychology 2023, 36: 184-191. PMID: 38377244, PMCID: PMC10880491, DOI: 10.1080/08995605.2022.2156200.Peer-Reviewed Original ResearchPost-traumatic stress disorderRisky alcohol useAlcohol useRisky drinkersProspective associationsCognitive functioning changesAlcohol misuseCo-occurring alcohol misusePosttraumatic stress symptomsFuture clinical trialsPTSD symptomsComplex traumaPsychedelic-assisted therapyStress disorderStress symptomsClinical characteristicsClinical trialsDMT treatmentPsychedelic treatmentTraditional interventionsTreatment programSignificant reductionSymptomsRespondersTreatment
2022
Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
Kelmendi B, Kichuk S, DePalmer G, Maloney G, Ching T, Belser A, Pittenger C. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon 2022, 8: e12135. PMID: 36536916, PMCID: PMC9758406, DOI: 10.1016/j.heliyon.2022.e12135.Peer-Reviewed Original ResearchObsessive-compulsive disorderTreatment of OCDPsychedelic treatmentTreatment-resistant obsessive-compulsive disorderRefractory obsessive-compulsive disorderOCD symptomsPsychological effectsSerotonin systemSingle experimental studyRecreational usersBrain serotonin systemTreatment of patientsClassic psychedelicsQuality of lifePsilocybinSymptomatic improvementCase reportClinical dataTherapeutic potentialEmotionsPatientsDisordersTreatmentNumber of conditionsCompulsionThe perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey.
Reynolds L, Barnett B, Weleff J, Morunga E, Wells A, Stack A, Akroyd A, Hoeh N, Sundram F, Muthukumaraswamy S, Lawrence N, Evans W. The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey. Palliative & Supportive Care 2022, 22: 664-673. PMID: 36325995, DOI: 10.1017/s1478951522001481.Peer-Reviewed Original ResearchHealth-care practitionersCross-sectional surveyPsychedelic-assisted therapyPatients to trialsIndigenous perspectives of healthEnd-of-life contextCancer patientsEnd-of-lifePerspective of healthVulnerable cancer patientsMind-altering experiencesNew Zealand participantsExistential distressConvenience sampleNew ZealandPsychedelic treatmentParticipantsPractitionersNew Zealand samplePerceptionCancerPatientsZealandAdvanced diseaseTrialsModels of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model
Brennan W, Belser A. Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. Frontiers In Psychology 2022, 13: 866018. PMID: 35719571, PMCID: PMC9201428, DOI: 10.3389/fpsyg.2022.866018.Peer-Reviewed Original ResearchClinical trialsEvidence-based therapiesPsychedelic-Assisted PsychotherapyPsychiatric indicationsPAP treatmentTreatment outcomesTherapeutic benefitDrug AdministrationPsychedelic treatmentSupportive psychotherapyTherapeutic interventionsStudy therapistsPsychedelic medicineTreatmentTherapist interventionsCurrent standardClinical domainsClinical orientationTherapist trainingTrialsTherapeutic changeResearch standardizationTherapy modelInterventionCurrent article brieflyPsychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans
Mangini P, Averill L, Davis A. Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans. Journal Of Psychedelic Studies 2022, 5: 149-155. DOI: 10.1556/2054.2021.00176.Peer-Reviewed Original ResearchPost-traumatic stress symptomsAlcohol misusePsychedelic treatmentAlcohol useCo-occurring alcohol misuseStress symptomsAnonymous internet-based surveyNovel treatment developmentRigorous longitudinal studiesUnique treatment needsPharmacologic treatmentPsychological flexibilityPsychedelic-assisted therapyInternet-based surveyTreatment needsAlcohol consumptionSymptomsClinical programsComplex sequelaeTreatment developmentCombat exposureLongitudinal studyTreatmentRetrospective reportsVeterans
2021
Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States
Davis A, Agin-Liebes G, España M, Pilecki B, Luoma J. Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. Journal Of Psychoactive Drugs 2021, 54: 309-318. PMID: 34468293, DOI: 10.1080/02791072.2021.1971343.Peer-Reviewed Original ResearchConceptsEffects of psychedelicsPsychedelic-assisted therapyMental health treatmentPsychedelic treatmentClinical psychologistsPsychedelic therapyPsychedelic drugsPsychedelic experienceHealth treatmentNeurocognitive riskPsychologistsPsychedelicsPositive beliefsElectronic survey studyFavorable attitudesReduce stigmaParticipantsBeliefsIncreased educationSurvey studyUnited StatesAttitudesIncreased knowledgeTherapeutic useTreatment
2020
Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity
Preller KH, Duerler P, Burt JB, Ji JL, Adkinson B, Stämpfli P, Seifritz E, Repovš G, Krystal JH, Murray JD, Anticevic A, Vollenweider FX. Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity. Biological Psychiatry 2020, 88: 197-207. PMID: 32111343, DOI: 10.1016/j.biopsych.2019.12.027.Peer-Reviewed Original ResearchConceptsFunctional connectivityBaseline connectivityResting-state functional connectivityGlobal functional connectivityBrain-wide connectivityHealthy human participantsPersonalized medicine approachPeak effectUse of psilocybinMechanism of actionSerotonin 2ATime-dependent mannerCrossover studyPredictive markerPsychedelic treatmentMedicine approachReceptor systemSensory regionsClinical contextTime pointsAssociative regionsDifferent test daysAdministrationTest dayTime-dependent changes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply